Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Alkermes Plc (ALKS)  
$24.68 0.24 (0.98%) as of 4:30 Fri 4/26


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 183,678,000
Market Cap: 4.53(B)
Last Volume: 775,760 Avg Vol: 773,595
52 Week Range: $23.37 - $33.63
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Delivery

Member Indexes:

    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  581
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Alkermes is a biopharmaceutical company. Co. has a portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia; ARISTADA INITIO, which is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults; and VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 35,000
Total Buy Value $0 $0 $0 $815,735
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 15,666 15,666 89,488 206,962
Total Sell Value $454,291 $454,291 $2,700,159 $6,056,962
Total People Sold 3 3 4 6
Total Sell Transactions 3 3 7 12
End Date 2024-01-28 2023-10-27 2023-04-28 2022-04-28

   
Records found: 1496
  Page 7 of 60  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Pops Richard F Director and CEO, Alkermes plc   •       •      –    2023-02-20 4 D $28.07 $1,491,780 D/D (53,145) 1,034,867     -
   Pops Richard F Director and CEO, Alkermes plc   •       •      –    2023-02-20 4 A $0.00 $0 D/D 119,713 1,088,012     -
   Gaffin David Joseph EVP, CLO, Alkermes, Inc.   •       •      –    2023-02-20 4 D $28.07 $185,739 D/D (6,617) 117,938     -
   Gaffin David Joseph EVP, CLO, Alkermes, Inc.   •       •      –    2023-02-20 4 A $0.00 $0 D/D 15,468 122,486     -
   Gaffin David Joseph EVP, CLO, Alkermes, Inc.   •       •      –    2023-02-20 4 OE $0.00 $0 D/D 7,036 109,087     -
   Brown Iain Michael SVP, Chief Financial Officer   •       •      –    2023-02-20 4 D $28.07 $121,150 D/D (4,316) 74,530     -
   Brown Iain Michael SVP, Chief Financial Officer   •       •      –    2023-02-20 4 A $0.00 $0 D/D 10,086 77,496     -
   Brown Iain Michael SVP, Chief Financial Officer   •       •      –    2023-02-20 4 OE $0.00 $0 D/D 4,589 68,760     -
   Jackson Blair Curtis EVP, Chief Operating Officer   •       •      –    2023-02-20 4 D $28.07 $121,150 D/D (4,316) 104,313     -
   Jackson Blair Curtis EVP, Chief Operating Officer   •       •      –    2023-02-20 4 A $0.00 $0 D/D 10,086 107,279     -
   Jackson Blair Curtis EVP, Chief Operating Officer   •       •      –    2023-02-20 4 OE $0.00 $0 D/D 4,589 98,543     -
   Nichols Christian Todd SVP, Chief Commercial Officer   •       •      –    2023-02-18 4 D $28.07 $55,045 D/D (1,961) 25,304     -
   Nichols Christian Todd SVP, Chief Commercial Officer   •       •      –    2023-02-18 4 OE $0.00 $0 D/D 6,230 27,265     -
   Hopkinson Craig C. EVP R&D, Chief Medical Officer   •       •      –    2023-02-18 4 D $28.07 $74,554 D/D (2,656) 24,060     -
   Hopkinson Craig C. EVP R&D, Chief Medical Officer   •       •      –    2023-02-18 4 OE $0.00 $0 D/D 8,722 26,716     -
   Landine Michael J SVP, Corp Dev., Alkermes, Inc.   •       •      –    2023-02-18 4 D $28.07 $57,965 D/D (2,065) 234,602     -
   Landine Michael J SVP, Corp Dev., Alkermes, Inc.   •       •      –    2023-02-18 4 OE $0.00 $0 D/D 4,361 236,667     -
   Gaffin David Joseph EVP, CLO, Alkermes, Inc.   •       •      –    2023-02-18 4 D $28.07 $54,596 D/D (1,945) 102,051     -
   Gaffin David Joseph EVP, CLO, Alkermes, Inc.   •       •      –    2023-02-18 4 OE $0.00 $0 D/D 6,230 103,996     -
   Brown Iain Michael SVP, Chief Financial Officer   •       •      –    2023-02-18 4 D $28.07 $55,158 D/D (1,965) 64,171     -
   Brown Iain Michael SVP, Chief Financial Officer   •       •      –    2023-02-18 4 OE $0.00 $0 D/D 6,230 66,136     -
   Jackson Blair Curtis EVP, Chief Operating Officer   •       •      –    2023-02-18 4 D $28.07 $75,312 D/D (2,683) 93,954     -
   Jackson Blair Curtis EVP, Chief Operating Officer   •       •      –    2023-02-18 4 OE $0.00 $0 D/D 8,722 96,637     -
   Daglio David Angelo Jr. Director   •       •      –    2023-02-10 4 OE $0.00 $0 D/D 4,445 15,169     -
   Mckeon Brian P Director   •       •      –    2023-02-10 4 OE $0.00 $0 D/D 4,445 15,169     -

  1496 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 7 of 60
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed